pyrazolin
fivememb
ring
heterocycl
two
adjac
nitrogen
atom
within
ring
one
endocycl
doubl
bond
basic
natur
also
known
dihydropyrazol
chemistri
close
relat
pyrazol
accord
heterocycl
nomenclatur
pyrazolin
requir
nitrogen
atom
number
structur
three
wellknown
tautomer
structur
pyrazolin
name
figur
howev
among
tautomer
structur
common
pyrazolin
deriv
electronrich
nitrogen
heterocycl
play
import
role
divers
biolog
activ
among
deriv
pyrazolin
seem
attract
pyrazolinetyp
deriv
heterocycl
compound
wide
occur
natur
form
alkaloid
vitamin
pigment
constitu
plant
anim
cell
accord
xray
analysi
pyrazolin
ring
structur
fivememb
dihydropyrazol
ring
envelop
conform
carbon
atom
deviat
almost
planar
system
four
atom
heterocycl
ring
insolubl
water
solubl
propylen
glycol
lipophil
charact
divers
substitut
pyrazolin
deriv
embed
varieti
function
group
import
biolog
activ
agent
huge
amount
research
activ
direct
toward
class
compound
pyrazolin
deriv
typic
ict
intramolecular
charg
transfer
compound
known
kind
fluoresc
brighten
agent
strong
blue
fluoresc
solut
classic
synthesi
compound
stimul
pioneer
work
fischer
late
centuri
reaction
aldehyd
keton
hydrazin
becam
one
popular
method
prepar
method
hydrazon
form
intermedi
subsequ
cycliz
presenc
suitabl
cycliz
reagent
like
acet
acid
altern
rout
involv
cycloaddit
nitrileimin
doubl
bond
arylmethylen
aryliden
deriv
activ
methylen
compound
well
acryl
cinnam
acid
deriv
discoveri
class
compound
consid
effici
drug
provid
outstand
case
histori
modern
drug
develop
also
point
unpredict
pharmacolog
activ
structur
modif
prototyp
drug
molecul
gener
pyrazolin
deriv
display
broad
spectrum
potenti
pharmacolog
activ
wide
medic
applic
last
decad
signific
interest
research
heterocycl
chemistri
direct
substitut
deriv
section
review
focus
recent
develop
pyrazolin
along
biolog
properti
regular
literatur
patent
field
recent
import
review
publish
pyrazolin
compound
present
review
cast
light
recent
patent
literatur
direct
toward
therapeut
applic
pyrazolin
period
patent
activ
review
includ
world
intellectu
proprietari
organ
wipo
unit
state
patent
trademark
offic
uspto
european
patent
offic
ep
german
offen
de
spain
es
china
cn
korea
kr
patent
figur
illustr
distribut
patent
period
obvious
highest
activ
therapeut
applic
pyrazolin
one
attract
subject
intens
research
pyrazolin
deriv
cannabinoid
receptor
type
antagonist
due
highli
fruit
therapeut
featur
receptor
antagonist
good
prospect
mani
therapeut
area
smoke
alcohol
addict
well
cognit
impair
recent
new
chemic
entiti
nce
antagonist
properti
structur
relat
rimonab
disclos
academ
research
group
sever
pharmaceut
compani
well
consider
number
antagonist
bioisoster
deriv
rimonab
replac
pyrazol
moieti
heterocycl
analog
like
pyrazolin
recent
marti
et
al
report
onepot
prepar
cinchonidin
salt
acid
use
intermedi
prepar
cannabinoid
neutral
antagonist
method
effici
avoid
isol
intermedi
produc
product
good
yield
enantiomer
excess
also
synthesi
acid
hydrazid
use
modul
achiev
yoo
et
al
receptor
bind
assay
pyrazolin
hydrochlorid
show
affin
far
pyrazolin
deriv
gener
structur
claim
use
treatment
obes
schizophrenia
prepar
cannabinoid
receptor
ligand
n
report
soler
et
al
solid
solut
andor
solid
dispers
racem
enantiom
prepar
effici
patent
result
achiev
vela
hernandez
prepar
n
cannabinoid
neutral
antagonist
treatment
food
intak
disord
context
mcelroy
chorvat
achiev
prepar
substitut
amid
cannabinoid
receptor
antagonistsinvers
agonist
use
treat
obes
diabet
dyslipidemia
cardiovascular
disord
andor
hepat
disord
deriv
report
lang
et
al
potent
receptor
antagonist
compound
show
lower
lipophil
charact
dramat
chang
replac
arylsulfonyl
group
dialkylaminosulfonyl
moieti
one
compound
exhibit
highest
receptor
affin
well
potent
antagonist
activ
high
subtyp
select
sulfonamidecontain
pyrazolin
deriv
gener
structur
prepar
buschmann
et
al
use
modul
compound
prepar
via
multistep
synthesi
start
acid
pyrazolin
show
high
affin
receptor
valu
nm
number
analog
prepar
srivastava
et
al
evalu
appetit
suppress
bodi
weight
reduct
anim
model
bisulf
salt
acid
acid
show
signific
bodi
weight
reduct
vivo
attribut
antagonist
activ
togeth
favor
pharmacokinet
profil
donohu
et
al
use
radiolabel
ligand
n
sulfonyl
imag
receptor
vivo
positron
emiss
tomographi
pet
understand
import
neuropsychiatr
disord
also
substitut
pyrazolin
deriv
report
fisasescasani
buschmann
evalu
prevent
weight
gain
report
multistep
synthesi
pyrazolin
deriv
start
ethyl
pyruv
compound
show
valu
nm
test
vitro
rat
receptor
subtyp
consequ
buschmann
et
al
report
prepar
pyrazolin
deriv
cannabinoid
receptor
inhibitor
treat
variou
diseas
lang
et
al
report
reaction
pentylhydrazono
acet
acid
ethyl
ester
nchlorosuccinimid
nc
follow
situ
treatment
styren
hydrolysi
amid
hydrochlorid
afford
pyrazolin
latter
compound
show
high
affin
cannabinoid
receptor
agonist
activ
receptor
also
use
treatment
multipl
sclerosi
traumat
brain
injuri
pyrazol
deriv
prepar
yildirim
et
al
compound
contain
pyrazolin
structur
use
receptor
modul
pyrazolin
exhibit
pki
valu
respect
cannabinoid
receptor
affin
assay
indolinesubstitut
pyrazolin
deriv
report
cannabinoid
receptor
modul
torrensjov
et
al
compound
gener
structur
test
cannabinoid
activ
vivo
addit
azepan
azocanesubstitut
pyrazolin
deriv
also
prepar
torrensjov
et
al
prepar
octahydropentalen
cycloalkanesubstitut
pyrazolin
deriv
respect
achiev
torrensjov
et
al
select
compound
gener
formula
test
vivo
cannabinoid
activ
also
prodrug
pyrazolin
compound
prepar
torrensjov
et
al
receptor
antagonist
recent
synthes
achiev
yenesminguez
torrensjov
synthes
pyrazolin
deriv
investig
cancer
treatment
prophylaxi
pyrazolin
could
success
employ
treatment
andor
cancer
prophylaxi
mani
type
rang
brain
bone
mouth
esophagu
stomach
liver
bladder
pancrea
cervix
lung
breast
colon
rectum
prostat
cancer
sever
novel
thiazolonebas
compound
contain
framework
report
havrylyuk
et
al
synthes
compound
evalu
vitro
cyctotox
activ
test
compound
display
promis
anticanc
activ
versu
varieti
cancer
type
includ
leukemia
melanoma
lung
colon
ovarian
renal
prostat
breast
cancer
cell
line
among
seri
compound
show
effici
anticanc
potenc
found
activ
select
influenc
colon
cancer
cell
line
especi
log
bhat
et
al
prepar
substitut
pyrazolin
deriv
evalu
vitro
cytotox
activ
panel
human
cancer
cell
line
eight
compound
show
mark
activ
screen
compound
antineoplast
activ
seri
pyrazolinebear
benzimidazol
versu
full
nci
cell
panel
report
shahrayar
et
al
compound
demonstr
best
cytotox
properti
high
select
certain
cell
line
includ
leukemia
ccrfcem
cell
line
valu
respect
pyrazol
deriv
report
manna
et
al
evalu
antineoplast
activ
inhibitori
effect
pglycoproteinmedi
multidrug
resist
protein
confer
resist
tumor
cell
decreas
drug
accumul
within
tumor
cell
compound
found
activ
blocker
johnson
et
al
synthes
pyrazolin
deriv
analog
natur
cisstilbin
deriv
replac
ethylenebridg
pyrazolin
heterocycl
test
anticanc
activ
report
roecker
et
al
mitot
kinesin
spindl
protein
ksp
inhibitor
valu
nm
cell
valu
nm
fuse
pyrazolin
deriv
cyclolignan
report
evalu
cytotox
activ
cultur
cell
murin
leukemia
colon
carcinoma
lung
carcinoma
inden
fuse
seri
pyrazolin
substitut
benzen
sulfonamid
sulfonylurea
sulfonylthiourea
scaffold
deriv
thiazolidinon
thiazolin
ring
system
synthes
rostom
evalu
antitumor
activ
eight
compound
show
promis
broadspectrum
antitumor
activ
test
subpanel
tumor
cell
line
prepar
pyrazol
deriv
relat
structur
target
pyrazolin
achiev
coleman
et
al
dihydropyrazol
compound
formula
use
treat
cellular
prolif
diseas
treat
disord
associ
ksp
kinesin
activ
inhibit
ksp
kinesin
breslin
et
al
report
prepar
deriv
potent
mitot
kinesin
inhibitor
antineoplast
activ
compound
evalu
kinesin
atpas
vitro
assay
use
human
ksp
motor
domain
reveal
potent
bind
affin
compound
prepar
start
precursor
demonstr
valu
gli
protein
play
pivot
role
cell
prolifer
apoptosi
also
report
block
gli
gene
import
initi
dna
damag
earli
sphase
lead
cell
death
human
carcinoma
et
al
report
synthesi
dihydropyrazol
carboxamid
use
kit
diagnosi
treatment
cancer
express
gli
polypeptid
particular
polypeptid
compound
evalu
gli
polypeptid
inhibitori
activ
identifi
activ
antitumor
candid
havrylyuk
et
al
select
influenc
leukemia
subpanel
tumor
cell
line
anoth
cancer
attract
target
sinc
directli
involv
apoptosi
induct
process
prepar
fuse
dihydropyrazol
signal
transduct
inhibitor
synthes
sawyer
et
al
instanc
ethyliden
amino
treat
sodium
hydrid
nah
dimethylformamid
dmf
h
afford
product
yield
select
pyrazolin
valu
type
receptor
ozdemir
et
al
prepar
deriv
studi
antiepilept
action
maxim
electroshock
seizur
me
subcutan
pentylenetetrazol
test
compound
found
protect
me
subcutan
metrazol
scmet
mgkg
dose
level
sever
synthes
singh
et
al
evalu
anticonvuls
activ
synthes
pyrazolin
exhibit
anticonvuls
activ
reflect
protect
observ
versu
ptzinduc
seizur
compound
exhibit
anticonvuls
potenti
via
inhibit
oxid
certain
substrat
set
pyrazolin
deriv
prepar
shishikura
et
al
use
kainic
acid
neurocytotox
inhibitor
synthes
deriv
show
noncompetit
antagon
versu
nonnmethyldaspart
nmda
type
ionotrop
transmembran
receptor
glutam
ampa
acid
receptor
use
nerv
cell
protector
antiepilept
therapi
particularli
pyrazolin
deriv
pyridin
show
versu
ampa
receptor
respect
quaternari
ammonium
salt
substitut
pyrazolin
compound
prepar
torrensjov
et
al
evalu
use
medica
treatment
human
anim
neurocytotox
pyrazolin
deriv
prepar
methyl
methyl
iodid
synthes
pyrazolin
evalu
neurocytotox
inhibitori
effect
deriv
show
decent
antidepress
activ
reduc
immobl
time
mgkg
dose
level
relationship
sar
point
view
found
substitu
phenyl
ring
pyrazolin
ring
increas
antidepress
activ
replac
group
bromo
methyl
substitu
neg
impact
antidepress
properti
prasad
et
al
synthes
gener
formula
evalu
antidepress
activ
pyrazolin
deriv
found
reduc
immobl
time
mgkg
dose
level
found
compound
electronreleas
group
aromat
ring
pyrazolin
posit
dramat
enhanc
antidepress
activ
compar
pyrazolin
substitu
aromat
ring
similarli
deriv
synthes
investig
antidepress
activ
porsolt
test
forc
swim
test
albino
mice
monoamin
oxidas
mao
inhibitor
wellestablish
antidepress
agent
gokhankelekci
et
al
synthes
sever
pyrazolin
deriv
evalu
antidepress
potenti
via
measur
mao
inhibitori
activ
addit
anxiolyt
monoamin
oxidasea
maoa
monoamin
oxidaseb
maob
inhibitori
activ
also
evalu
vivo
andor
vitro
test
synthes
compound
show
high
activ
maoa
maob
isoform
chimenti
et
al
report
synthesi
seri
pyrazol
deriv
test
pharmacolog
activ
mao
inhibitor
test
compound
show
inhibitori
activ
within
micromolar
rang
high
select
versu
clinic
import
isozym
maoa
antidepressantlik
activ
compound
x
analog
found
favor
compar
clinic
use
fluoxetin
action
suggest
mediat
modul
cn
serotonin
pathway
jayaprakash
et
al
synthes
seri
carbothioamid
pyrazolin
deriv
design
mycobactin
analog
mycobacteri
siderophor
evalu
antidepress
mao
inhibitori
activ
interestingli
found
compound
antitubercular
potenti
act
also
select
inhibitor
rat
liver
maob
substitut
pyrazol
deriv
found
select
inhibit
maoa
maob
isoform
manna
et
al
synthes
novel
seri
pyrazol
deriv
studi
abil
select
inhibit
mao
swine
kidney
oxidas
bovin
serum
amin
oxidas
pyrazolin
show
potent
mao
inhibitor
ki
valu
nm
seri
pyrazol
synthes
chimenti
et
al
assay
mao
inhibitor
compound
show
inhibitori
activ
micromolar
rang
high
select
toward
maoa
isozym
addit
found
use
adjuv
therapi
treatment
neurodegen
disord
parkinson
diseas
alzheim
diseas
bi
deriv
synthes
screen
antiinflammatori
properti
util
vivo
acut
carrageenaninduc
paw
edema
standard
method
rat
set
pyrazolin
also
demonstr
decent
inhibitori
activ
versu
prostaglandin
respons
fever
dose
level
mgkg
bispyrazolin
deriv
exhibit
consider
antiinflammatori
properti
compound
show
remark
antiinflammatori
activ
rel
indomethacin
standard
refer
lower
ulcer
index
valu
also
novel
bi
deriv
synthes
research
group
screen
antiinflammatori
ulcerogen
activ
well
synthes
compound
show
advanc
antiinflammatori
properti
lower
ulcerogen
liabil
standard
use
drug
seri
report
amir
et
al
screen
antiinflammatori
analges
activ
benzenesulfonamid
deriv
synthes
rathish
et
al
screen
antiinflammatori
activ
pyrazolin
deriv
found
activ
celecoxib
throughout
studi
rani
et
al
synthes
seri
pyrazolin
deriv
pendent
indol
moieti
report
evalu
antiinflammatori
activ
carrageenaninduc
edema
albino
rat
oral
dosag
regimen
mgkg
synthes
pyrazolin
show
promis
antiinflammatori
activ
phydroxyphenyl
indol
found
potent
deriv
seri
show
higher
percentil
edema
inhibit
along
lower
ulcerogen
liabil
acut
toxic
phenylbutazon
standard
drug
compound
bear
electron
withdraw
nitro
group
aryl
moieti
show
good
activ
compar
standard
drug
pentazocin
diclofinac
sodium
rathish
et
al
synthes
seri
pyrazolinesbear
benzen
sulfonamid
evalu
antiinflammatori
activ
among
test
compound
sever
show
promis
antiinflammatori
activ
deriv
prepar
screen
lipoxygenas
lox
inhibitori
activ
pyrazol
deriv
contain
thiocarbamoyl
group
report
gokhankelekci
et
al
synthes
seri
pyrazolin
test
vivo
antiinflammatori
activ
two
differ
bioassay
name
carrageenaninduc
edema
acet
acidinduc
increas
capillari
permeabl
mice
moreov
analges
ulcerogen
activ
also
investig
seri
substitut
synthes
khode
et
al
screen
vivo
antiinflammatori
analges
activ
among
prepar
compound
pyrazolin
deriv
exhibit
signific
antiinflammatori
activ
model
acut
inflamm
shoman
et
al
synthes
group
nodon
deriv
evalu
antiinflammatori
activ
use
carrageenaninduc
rat
paw
edema
compar
indomethacin
known
standard
abil
prepar
deriv
induc
gastric
toxic
also
evalu
prepar
seri
show
signific
antiinflammatori
activ
higher
safeti
margin
indomethacin
regard
gastric
toxic
nodon
group
incorpor
parent
pyrazolin
deriv
caus
nonsignific
reduct
antiinflammatori
activ
mark
decreas
gastric
ulcer
induc
pyrazolin
lack
group
pyrazolin
deriv
contain
benzoxazol
benzimidazol
moieti
report
kaplancikli
et
al
synthes
compound
evalu
antinocicept
activ
compound
exhibit
signific
antinocicept
activ
hot
plate
acet
acidinduc
writh
test
pyrazolin
synthes
godoy
et
al
test
antinocicept
activ
moreov
godoy
et
al
also
investig
whether
pain
relief
effect
mediat
spinal
noradrenerg
serotonerg
system
result
show
unlik
standard
dipyron
spinal
serotonin
receptor
involv
antinocicept
induc
sever
deriv
synthes
ozdemir
et
al
evalu
antimicrobi
activ
escherichia
coli
bacillu
cereu
salmonella
typhimurium
streptococcu
faecali
staphylococcu
aureu
aeromona
hydrophila
candida
glabrata
candida
albican
signific
level
activ
observ
context
abdelwahab
et
al
report
synthesi
sever
aryl
evalu
antibacteri
antifung
activ
synthes
compound
show
enhanc
antimicrobi
activ
control
drug
cyano
aminocarbonyl
ethoxycarbonyl
deriv
prepar
abunada
et
al
screen
antimicrobi
activ
e
coli
aureu
asperagillu
flavu
c
albican
bhatt
et
al
synthes
sever
substitut
pyrazolin
potenti
antimicrobi
agent
synthes
compound
found
remark
activ
bacillu
megaterium
bacillu
subtili
e
coli
mycobacterium
tuberculosi
synthesi
pyrazolin
deriv
naproxen
repres
compound
achiev
udupi
et
al
biolog
evalu
show
compound
seri
show
signific
dual
antimicrobi
antiinflammatori
activ
bharmal
et
al
synthes
pyrazolin
deriv
antimicrobi
activ
salmonella
typhosa
aspergillu
niger
basawaraj
et
al
report
synthesi
pendent
benzofuran
b
test
antimicrobi
activ
gramposit
gramneg
bacteria
repres
aureu
e
coli
compound
reveal
potent
antibacteri
effect
versu
gramposit
bacteria
contrast
antimicrobi
effect
significantli
reduc
case
gramneg
strain
new
pyrazolin
nphenylpyrazolin
b
prepar
desai
et
al
evalu
antimicrobi
activ
synthes
compound
exhibit
activ
gramposit
bacteria
jamod
et
al
report
synthesi
b
evalu
antimicrobi
properti
aureu
e
coli
proteu
mirabili
pseudomona
aeruginosa
pyrazolin
deriv
found
moder
antibacteri
activ
seri
chlorofluoropyrazolin
prepar
karthikeyan
et
al
pyrazolin
show
signific
antibacteri
antifung
activ
treatment
chalcon
nitromethan
michael
addit
condit
follow
subsequ
cycliz
thiosemicarbazid
basic
reflux
condit
gave
pyrazolin
react
phenacyl
bromid
afford
thiazolesubstitut
pyrazolin
compound
show
signific
antimicrobi
activ
e
coli
niger
deriv
synthes
chimenti
et
al
evalu
vitro
antibacteri
activ
helicobact
pylori
pyrasolin
group
substitu
ring
show
highest
activ
h
pylori
metronidazoleresist
strain
minimum
inhibitori
concentr
mic
valu
mogilaiah
et
al
evalu
antibacteri
activ
pyrazolin
deriv
contain
moieti
repres
compound
prepar
compound
show
less
activ
standard
aminogylcosid
gentamycin
vijayvergiya
et
al
synthes
deriv
evalu
antibacteri
activ
new
pyrazolin
show
remark
antibacteri
activ
gramposit
bacteria
aureu
staphylococcu
albu
streptococcu
pyogen
streptococcu
viridan
gramneg
bacteria
e
coli
typhosa
wahe
khan
synthes
deriv
substitut
nalidix
acid
antibacteri
analges
agent
pyrazolin
found
signific
antibacteri
activ
gramneg
bacteria
possess
appreci
analges
activ
stirrett
et
al
synthes
pyrazolin
repres
compound
structur
similar
siderophor
evalu
abil
novel
antimicrobi
tuberculosi
yersinia
pesti
report
shenoy
et
al
test
antimicrobi
activ
compound
exhibit
potenti
antitubercular
activ
zampieri
et
al
report
synthesi
deriv
test
strain
c
albican
strain
tuberculosi
shaharyar
et
al
present
seri
substitut
phenyl
test
vitro
antimycobacteri
activ
pyrazolin
found
activ
agent
differ
strain
tb
mic
valu
deriv
synthes
mamolo
et
al
test
vitro
antimycobacteri
activ
latter
pyrazolin
deriv
show
interest
activ
differ
strain
tuberculosi
sever
n
ndisubstitut
thiocarbamoylthio
acetyl
deriv
synthes
ozdemir
et
al
shaharyar
et
al
evalu
vitro
antimycobacteri
activ
strain
potenti
benefit
medica
endow
antimycobacteri
antifung
charact
repres
valuabl
goal
sinc
associ
tb
mycot
infect
often
occur
immunocompromis
patient
far
repres
structur
pendent
ring
report
zampieri
et
al
test
vitro
antifung
antimycobacteri
activ
imidazolesubstitut
pyrazol
deriv
show
signific
antifung
activ
clinic
strain
c
albican
remark
antitubercular
activ
tuberculosi
seri
heterocyclicsubstitut
diphenyl
ether
deriv
pyrazol
synthes
evalu
activ
strain
mycobacterium
ten
compound
inhibit
growth
concentr
low
level
activ
found
compar
refer
drug
rifampicin
isoniazid
concentr
anoth
seri
substitut
phenyl
substitut
methanethion
deriv
synthes
ali
et
al
test
vitro
antitubercular
activ
tuberculosi
compound
found
activ
mic
valu
babu
et
al
evalu
biolog
activ
pyrazolinesbear
benzofuran
moieti
compound
found
antitubercular
effect
compound
synthes
hayat
et
al
test
vitro
antiamoeb
activ
versu
imss
strain
entamoeba
histolytica
result
show
compound
exhibit
promis
antiamoeb
activ
respect
varieti
thiazolo
deriv
repres
compound
achiev
budakoti
et
al
screen
antiamoeb
activ
hmi
imss
strain
e
histolytica
microdilut
method
compar
valu
standard
drug
metronidazol
also
author
synthes
novel
pd
ii
complex
budakoti
et
al
evalu
antiamoeb
activ
microdilut
method
imss
strain
e
histolytica
compar
result
standard
drug
metronidazol
palladium
complex
show
better
activ
correspond
ligand
pyrazolin
show
better
inhibitori
activ
indic
lower
valu
compar
metronidazol
similarli
husain
et
al
report
anoth
seri
pd
ii
complex
repres
activ
compound
seri
compound
less
activ
term
valu
howev
complex
activ
metronidazol
abid
et
al
synthes
seri
deriv
cycliz
mannich
base
thiosemicarbazid
evalu
vitro
antiamoeb
activ
e
histolytica
comparison
metronidazol
refer
drug
preliminari
sar
indic
substitut
phenyl
ring
pyrazolin
markedli
enhanc
antiamoeb
activ
moreov
compound
show
promis
antiamoeb
activ
valu
versu
metronidazol
anoth
new
seri
pyrazolin
deriv
synthes
cycliz
mannich
base
thiosemicarbazid
substitut
differ
cyclic
aromat
amin
screen
vitro
antiamoeb
activ
e
histolytica
pyrazolin
found
activ
compound
seri
pd
ii
complex
deriv
also
prepar
evalu
antiamoeb
activ
observ
previous
pd
ii
complex
exhibit
stronger
antiamoeb
activ
bhat
et
al
report
interest
bispyrazolin
prepar
cycliz
chalcon
thiosemicarbazid
basic
condit
investig
antiamoeb
activ
show
compound
aromat
substitu
thiocarbamoyl
group
activ
cyclic
group
semicarbazonebas
pyrazolin
deriv
repres
compound
design
drug
candid
chaga
diseas
american
trypanosomiasi
compound
show
inhibitori
activ
versu
trypanosoma
cruzi
low
nm
compound
analog
exhibit
antitrypanosom
activ
target
cystein
proteas
cruzain
interestingli
low
cellular
toxic
compound
prepar
seebach
et
al
togeth
other
compound
show
moder
activ
cruzi
new
nacetyl
nthiocarbamoyl
deriv
synthes
elsabbagh
et
al
test
broad
panel
virus
differ
cell
cultur
activ
compound
subtox
concentr
vaccinia
viru
lederl
strain
hel
cell
cultur
valu
yar
et
al
report
synthesi
new
pyrazolin
deriv
phenoxyacet
acid
synthes
deriv
test
vitro
cytotox
antivir
activ
addit
antivir
activ
acet
acid
show
maximum
cytotox
seri
seri
trisubstitut
pyrazolin
show
inhibit
flaviviru
infect
cell
cultur
identifi
highthroughput
screen
compound
librari
use
luciferaseexpress
west
nile
viru
wnv
infect
assay
arylr
pyrazolin
essenti
activ
wnv
pyrazolin
inhibitor
rna
synthesi
investig
point
viral
rna
polymeras
rna
helicas
viral
replic
enzym
potenti
target
liang
et
al
report
synthesi
deriv
inhibit
activ
picornaviru
coronaviru
simultan
compound
could
use
prevent
treat
diseas
caus
pecorino
viru
coronaviru
influenza
footandmouth
diseas
epidem
keratoconjunct
asept
mening
myocard
hepat
sever
acut
respiratori
syndrom
sar
silver
soderlund
synthes
insecticid
relat
pyrazolin
b
examin
mechan
action
base
electrophysiolog
pharmacolog
toxicolog
inform
eventu
found
compound
exert
insecticid
activ
via
neuron
target
turanzitouni
et
al
synthes
sever
studi
hypotens
activ
tailcuff
method
synthes
pyrazolin
show
appreci
hypotens
activ
compar
clonidin
refer
drug
seri
prepar
evalu
inhibitori
action
acylcoenzym
cholesterol
acyltransferas
acat
respons
format
cholesterol
precursor
acetoacetyl
coa
mevalon
pathway
pyrazolin
exampl
seri
show
vitro
inhibitori
activ
substitut
pyrazolin
deriv
gener
formula
acat
inhibit
activ
prepar
pharmaceut
composit
use
treatment
dyslipidemia
report
yenesminguez
torrensjov
camacho
et
al
synthes
new
seri
neural
nitric
oxid
synthas
nno
inhibitor
structur
attempt
find
new
compound
neuroprotect
activ
pyrazolin
show
highest
activ
inhibit
percentag
respect
also
et
al
synthes
evalu
seri
deriv
potenti
inhibitor
neuron
induc
nitric
oxid
synthas
nno
ino
novel
seri
pyrazolin
deriv
synthes
babu
et
al
evalu
antioxid
activ
variou
concentr
standard
ascorb
acid
pyrazolin
among
seri
synthes
compound
show
excel
antioxid
activ
compar
ascorb
acid
zhang
et
al
design
sever
pyrazolin
gener
formula
evalu
vivo
screen
tissu
select
androgen
receptor
modul
sarm
sar
investig
posit
well
core
pyrazolin
ring
anilid
linker
found
strong
electronwithdraw
group
posit
small
group
posit
optim
androgen
receptor
agonist
activ
jone
et
al
achiev
synthesi
pyrazolin
deriv
studi
dock
protein
receptor
homolog
model
result
studi
reveal
synthes
compound
exhibit
function
antagon
protein
receptor
seri
interest
androstano
pyrazolin
oxid
deriv
synthes
evalu
antiandrogen
activ
compar
cyproteron
posit
control
compound
show
better
antiandrogen
activ
refer
drug
fisasescasani
et
al
achiev
prepar
substitut
pyrazolin
order
use
combin
therapi
antidiabet
agent
human
urotensin
ii
receptor
hutr
member
famili
rhodopsinlik
gproteincoupl
receptor
gpcr
involv
modul
function
mani
tissu
organ
combinatori
scaffold
approach
report
olsson
build
librari
compound
four
divers
point
synthes
compound
provid
map
urotensin
ii
receptor
differenti
bind
receptor
aforement
exampl
pyrazolin
heterocycl
ring
mainli
use
structur
core
build
huge
varieti
biolog
activ
compound
versatil
pyrazolin
structur
semisatur
statu
provid
uniqu
spatial
configur
allow
variou
substitut
pattern
figur
show
eight
possibl
pattern
two
substitut
one
imagin
divers
case
three
substitu
among
report
activ
import
note
pyrazolinecontain
cytotox
compound
use
treatment
variou
cancer
type
also
act
cancer
chemoprevent
agent
concern
report
antimycobaterium
activ
pyrazolinecontain
compound
report
assay
util
vaccinestrain
infecti
strain
make
biolog
impact
doubt
evalu
compound
versu
multidrugresist
mrtb
extrem
drugresist
xdrtb
mycobacterium
strain
add
huge
valu
present
work
report
articl
hamper
lack
molecular
target
identif
report
biolog
activ
pyrazolinecontain
compound
base
cellbas
assay
author
report
anyth
possibl
molecular
target
far
kind
drug
develop
protocol
allow
conduct
structurebas
drug
design
approach
point
view
attent
given
molecular
basi
mode
action
henc
ration
drug
design
method
could
appli
druglik
candid
like
obtain
